pembrolizumab
merck
['pembro']
 #esmo22 s1801 randomized phase 2 trial of 3 doses of pembro preop (+15 postop doses) vs postop pembrolizumab showing efs of 72% vs 49% (p=0.004) benefiting multiple subgroups. 
Professor | Vice Chair of Clinical Research & Faculty Development | Thoracic & GI cancer researcher | Rutgers Cancer Institute of New Jersey | opinions my own